Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Genenta Science S.p.A. GNTA
$5.95
+$0.2 (3.30%)
На 18:05, 12 мая 2023
Ключевые показатели
-
Marketcap
108667452.00000000
-
week52high
9.33
-
week52low
3.90
-
Revenue
0
-
P/E TTM
-25
-
Beta
0.00000000
-
EPS
-0.54000000
-
Last Dividend
0.00000000
-
Next Earnings Date
26 апр 2023 г. в 04:00
Описание компании
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Genenta to Present at Upcoming Scientific and Investor Conferences
GlobeNewsWire
05 окт 2022 г. в 08:05
MILAN, Italy and NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical stage immune-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, will present at several upcoming scientific and investor conferences.
Genenta to Present at Upcoming Investor Conferences
GlobeNewsWire
07 сент 2022 г. в 07:00
MILAN, Italy and NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical stage immune-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, will present at several upcoming investor conferences in September and October.
Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA
GlobeNewsWire
13 мая 2022 г. в 07:30
MILAN, Italy and NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, will be presenting at several upcoming scientific congresses in May and June.
Genenta to Participate at Upcoming Investor Conferences
GlobeNewsWire
24 февр 2022 г. в 07:30
MILAN, Italy and NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer (Temferon™), announced today that management will be participating in the following upcoming investor conferences:
U.S. IPO Weekly Recap: 6 IPOs Debut Ahead Of The Shortened Holiday Week
Seeking Alpha
18 дек 2021 г. в 05:22
U.S. IPO Weekly Recap: 6 IPOs Debut Ahead Of The Shortened Holiday Week